Show simple item record

dc.contributor.authorGange, Stephen J
dc.contributor.authorSchneider, Michael F
dc.contributor.authorGrant, Robert M
dc.contributor.authorLiegler, Teri
dc.contributor.authorFrench, Audrey
dc.contributor.authorYoung, Mary
dc.contributor.authorAnastos, Kathryn
dc.contributor.authorWilson, Tracey E
dc.contributor.authorPonath, Claudia
dc.contributor.authorGreenblatt, Ruth
dc.date.accessioned2023-11-15T20:08:01Z
dc.date.available2023-11-15T20:08:01Z
dc.date.issued2006-01-01
dc.identifier.citationGange SJ, Schneider MF, Grant RM, Liegler T, French A, Young M, Anastos K, Wilson TE, Ponath C, Greenblatt R. Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure. J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):68-74. doi: 10.1097/01.qai.0000174652.40782.4e. PMID: 16340476.en_US
dc.identifier.issn1525-4135
dc.identifier.doi10.1097/01.qai.0000174652.40782.4e
dc.identifier.pmid16340476
dc.identifier.urihttp://hdl.handle.net/20.500.12648/13918
dc.description.abstractObjectives: To describe the prevalence of specific protease inhibitor (PI) and nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations and the relationship between the presence of these mutations and immunologic outcomes following PI/NNRTI initiation among a cohort of HIV-1-infected women. Methods: Viral genotypic resistance testing was done for 366 women enrolled in the Women's Interagency HIV Study at the visit immediately prior to 1st reported use of PI or NNRTI (baseline) and at the visit approximately 1 year after PI/NNRTI initiation. We modeled the changes in CD4+ T-cell counts and HIV RNA levels approximately 1 year after therapy initiation as a function of baseline and follow-up markers, type of antiretroviral therapy used, and resistance mutations. Results: At baseline, 52% of women showed only nucleoside reverse transcriptase inhibitor (NRTI) mutations, 38% showed no mutations, and 10% showed PI or NNRTI mutations. Only 40% of women showed viral response (HIV-1 RNA < or = 80 copies/mL) 1 year after initiating a PI or NNRTI. Among those without a viral response, 54% developed PI or NNRTI mutations. NNRTI (among those with baseline NRTI mutations) and PI resistance mutations were associated with better CD4+ cell count changes (mean increase of 118 cells/mm3 and 64 cells/mm3, respectively, as compared with viral nonresponders with no PI or NNRTI mutations). Conclusions: In this population-based cohort, virologic failure with PI or NNRTI resistance was common. Viremia with these resistance mutations was associated with preserved CD4+ T-cell count responses, providing evidence of reduced virulence or viral fitness.en_US
dc.language.isoenen_US
dc.publisherOvid Technologies (Wolters Kluwer Health)en_US
dc.relation.urlhttps://journals.lww.com/jaids/fulltext/2006/01010/genotypic_resistance_and_immunologic_outcomes.11.aspxen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPharmacology (medical)en_US
dc.subjectInfectious Diseasesen_US
dc.titleGenotypic Resistance and Immunologic Outcomes Among HIV-1-Infected Women With Viral Failureen_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleJAIDS Journal of Acquired Immune Deficiency Syndromesen_US
dc.source.volume41
dc.source.issue1
dc.source.beginpage68
dc.source.endpage74
dc.description.versionVoRen_US
refterms.dateFOA2023-11-15T20:08:05Z
dc.description.institutionSUNY Downstateen_US
dc.description.departmentCommunity Health Sciencesen_US
dc.description.degreelevelN/Aen_US
dc.identifier.issue1en_US


Files in this item

Thumbnail
Name:
genotypic_resistance_and_immun ...
Size:
182.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International